NSW Launches $96M RNA Manufacturing Facility to Advance Genomic Medicine

Construction has commenced on a state-of-the-art RNA research and pilot manufacturing facility at Macquarie University’s Wallumattagal campus in New South Wales. Supported by a $96 million investment from the NSW Government, this facility is poised to become Australia’s first of its kind and among a select few globally. It aims to advance the development of RNA-based vaccines and medical therapies for both human and veterinary applications.

The facility will enable the independent design and testing of a diverse array of RNA vaccines, therapeutics, and delivery technologies, thereby enhancing NSW’s sovereign capabilities in this sector. It is also equipped to manufacture RNA-based therapeutics across all three phases of clinical trials. Aurora Biosynthetics, a subsidiary of Myeloid Therapeutics, will operate the facility, under the oversight of RNA Australia—a newly established entity formed through a joint venture between the NSW Government, four NSW universities, and the Australian National University.

NSW Premier Chris Minns emphasized that the facility will not only generate employment and attract investment but also deliver potentially life-saving solutions. The initiative underscores the state’s commitment to bolstering its health and life sciences sector, which currently employs approximately 90,000 individuals, accounting for 40% of Australia’s workforce in this field.

For professionals in the genomics and medical research sectors, this development represents a significant advancement in RNA technology infrastructure within Australia. The facility is expected to foster innovation and collaboration, offering new avenues for research and development in genomic medicine.

Read the full news piece by clicking here. For more updates on developments in the genomics industry, follow InGeNA.